SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy
BiotechTV - News
00:00
Dual Targeting Advantage and Clinical Results
Marshall attributes strong results to using the native TACI receptor to bind BAFF and APRIL, reducing immune complexes.
Play episode from 06:49
Transcript
